- Home
- GPN vs RPRX Comparison
GPN vs RPRX Comparison
Compare GPN & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GPN | RPRX |
|---|---|---|
| Founded | 1967 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 16.4B |
| IPO Year | 2001 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GPN | RPRX |
|---|---|---|
| Price | $75.29 | $38.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 4 |
| Target Price | ★ $103.20 | $45.75 |
| AVG Volume (30 Days) | 2.4M | ★ 3.5M |
| Earning Date | 02-12-2026 | 02-10-2026 |
| Dividend Yield | 1.29% | ★ 2.28% |
| EPS Growth | ★ 34.30 | N/A |
| EPS | ★ 7.12 | 1.75 |
| Revenue | ★ $10,076,185,000.00 | $2,349,844,000.00 |
| Revenue This Year | N/A | $37.66 |
| Revenue Next Year | $4.10 | $2.34 |
| P/E Ratio | ★ $10.87 | $22.06 |
| Revenue Growth | ★ 22.33 | 3.70 |
| 52 Week Low | $65.93 | $25.28 |
| 52 Week High | $115.19 | $41.24 |
Technical Indicators
Market Signals| Indicator | GPN | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 45.32 |
| Support Level | $79.74 | $38.20 |
| Resistance Level | $81.99 | $39.46 |
| Average True Range (ATR) | 1.76 | 0.56 |
| MACD | -0.57 | -0.04 |
| Stochastic Oscillator | 3.33 | 35.93 |
Price Performance
Historical ComparisonAbout GPN Global Payments Inc.
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares. The merger added issuer processing operations.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.